- Slice of Manufacturing
- Posts
- Charles River and Gates Institute Partner on Lentiviral Vector Manufacturing
Charles River and Gates Institute Partner on Lentiviral Vector Manufacturing
Slice of Manufacturing Team
July 08, 2024
Key Highlights:
Charles River Laboratories and Gates Institute announce a CDMO partnership.
Gates Institute to develop GMP-grade lentiviral vectors for CAR T-cell therapies.
Collaboration aims to accelerate clinical and commercial manufacturing processes.
Source (Business Wire)
Notable Quotes:
“The cell therapy ecosystem that Gates Institute has created is exciting and we look forward to helping them advance the development of CAR-T therapies for hematological cancers. Our complementary strengths and concept to cure capabilities are well positioned to help move the science forward into the clinic and beyond for oncology patients.”
“We value this new partnership with Charles River, an industry leader in biopharmaceutical services. In the near term, this collaboration will accelerate the Gates Institute CAR-T programs with their plasmid and lentiviral vector production. Looking ahead to our long-term collaboration, we remain committed to advancing patient impact more broadly.”
Our Take:
This strategic collaboration between Charles River and the Gates Institute represents a significant advancement in the development of CAR T-cell therapies for hematological cancers. By leveraging Charles River’s established CDMO expertise and advanced manufacturing platforms, the Gates Institute can accelerate the production of GMP-grade lentiviral vectors, crucial for first-in-human clinical trials. This partnership not only promises to enhance the speed and efficiency of developing these innovative therapies but also underscores the importance of robust industry collaborations in advancing medical science and improving patient outcomes.